MedTrace Logo

Safety, Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).

NCT02695004 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2020-04-06

No results posted yet for this study

Summary

This is a study to evaluate safety, tolerability and PK of DKF-310 IM injection in healthy male volunteers.

Conditions

Interventions

DRUG

DKF-310

DRUG

Placebo

Sponsors & Collaborators

  • Dongkook Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02695004 on ClinicalTrials.gov